Showing 8131-8140 of 9459 results for "".
- Move Over CoolSculpting? Fat-freezing Ice Slurries May Be the Next Big Thing in Body Contouringhttps://practicaldermatology.com/news/fat-freezing-ice-slurries-may-be-the-next-big-thing-in-body-contouring/2460255/An injectable ice “slurry” may selectively reduce unwanted fat, according to research in pigs published in Plastic & Reconstructive Surgery.
- Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillershttps://practicaldermatology.com/news/revance-acquires-exclusive-us-distribution-rights-to-teoxane-sa-fillers-1/2460250/Revance Therapeutics, Inc. is the exclusive commercialization partner of Teoxane SA in the US. With a new distribution agreement just announced, Revance gains immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the
- Almirall on the Move with Three New Collabshttps://practicaldermatology.com/news/almirall-on-the-move-with-three-new-collabs/2460248/With three new strategic agreements, Almirall, S.A. is set to strengthen their early-stage research portfolio and expand their pipeline in medical dermatology. Alimirall and 23andMe have signed an agreement allowing Almirall to in-license 23
- It’s Gold and Silver for Sebacia with Sienna Acquisitionhttps://practicaldermatology.com/news/its-gold-and-silver-for-sebacia-with-sienna-acquisition/2460247/Mr. Chuck Abraham is the new Chief Executive Officer of Sebacia, Inc. Sebacia is preparing a targeted commercial launch of Sebacia Microparticles in the US for treatment of acne early in 2020 with plans to expand to additional territories later in th
- Study of Victoria's Secret Models Highlights Changing and Unattainable Beauty Standardshttps://practicaldermatology.com/news/study-of-victorias-secret-models-highlights-changing-and-unattainable-beauty-standards/2460242/While the average American woman's waist circumference and dress size has increased over the past 20 years, Victoria's Secret fashion models have become more slender, with a decrease in bust, waist, hips and dress size, though their waist to hip ratio (WHR) has remained constant, accordin
- FDA Approves Ortho Dermatologic’s Arazlo Lotion for Acnehttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-arazlo-lotion-for-acne/2460238/The FDA has approved the New Drug Application for ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. Ortho Dermatologic’s ARAZLO is the first tazarotene acne treatment available in a lotion form,
- Castle Creek Completes Acquisition of Fibrocell Sciencehttps://practicaldermatology.com/news/castle-creek-completes-acquisition-of-fibrocell-science/2460235/Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc. Both companies have advanced investigational therapies for the treatment of epidermolysis bullosa (EB) into late-stage clinical research. Prior to the acquisition, Fibrocell initiated a pivot
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- Keloid Breakthrough: Mount Sinai Researchers Show Keloid Shrinkage with Dupilumabhttps://practicaldermatology.com/news/keloid-breakthrough-mount-sinai-researchers-show-keloid-shrinkage-with-dupilumab/2460223/Keloid lesions exhibit increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy, Mount Sinai researchers report. Researchers, led by Emma Guttman-Yassky, MD, PhD, Vice Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York,